Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Nov;58(11):1179-1181.
doi: 10.1038/s41409-023-02033-0. Epub 2023 Aug 9.

GVHD prophylaxis with post-transplant cyclophosphamide results in lower incidence of GVHD and allows faster immunosuppressive treatment reduction compared to antithymocyte globulin in 10/10 HLA-matched unrelated allogeneic hematopoietic cell transplantation

François Dachy  1 , Sabine Furst  1 , Boris Calmels  2   3 , Thomas Pagliardini  1 , Samia Harbi  1 , Benjamin Bouchacourt  1 , Anne Calleja  1 , Claude Lemarie  2   3 , Aude Collignon  1 , Guillaume Morel  1 , Faezeh Legrand  1 , Elena Bekrieva  1 , Angela Granata  1 , Pierre Jean Weiller  1 , Christian Chabannon  2   3   4 , Jean Marc Schiano  1 , Norbert Vey  1   4 , Didier Blaise  1   5 , Raynier Devillier  6   7
Affiliations

GVHD prophylaxis with post-transplant cyclophosphamide results in lower incidence of GVHD and allows faster immunosuppressive treatment reduction compared to antithymocyte globulin in 10/10 HLA-matched unrelated allogeneic hematopoietic cell transplantation

François Dachy et al. Bone Marrow Transplant. 2023 Nov.
No abstract available

PubMed Disclaimer

References

    1. Finke J, Bethge WA, Schmoor C, Ottinger HD, Stelljes M, Zander AR, et al. Standard graft-versus-host disease prophylaxis with or without anti-T-cell globulin in haematopoietic cell transplantation from matched unrelated donors: a randomised, open-label, multicentre phase 3 trial. Lancet Oncol. 2009;10:855–64. - DOI - PubMed
    1. Walker I, Panzarella T, Couban S, Couture F, Devins G, Elemary M, et al. Addition of anti-thymocyte globulin to standard graft-versus-host disease prophylaxis versus standard treatment alone in patients with haematological malignancies undergoing transplantation from unrelated donors: final analysis of a randomised, open-label, multicentre, phase 3 trial. Lancet Haematol. 2020;7:e100–11. - DOI - PubMed
    1. Luznik L, O’Donnell PV, Symons HJ, Chen AR, Leffell MS, Zahurak M, et al. HLA-haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, posttransplantation cyclophosphamide. Biol Blood Marrow Transpl. 2008;14:641–50. - DOI
    1. Pagliardini T, Harbi S, Fürst S, Castagna L, Legrand F, Faucher C, et al. Post-transplantation cyclophosphamide-based haploidentical versus Atg-based unrelated donor allogeneic stem cell transplantation for patients younger than 60 years with hematological malignancies: a single-center experience of 209 patients. Bone Marrow Transpl. 2019;54:1067–76. - DOI
    1. Devillier R, Legrand F, Rey J, Castagna L, Fürst S, Granata A, et al. HLA-matched sibling versus unrelated versus haploidentical related donor allogeneic hematopoietic stem cell transplantation for patients aged over 60 years with acute myeloid leukemia: a single-center donor comparison. Biol Blood Marrow Transpl. 2018;24:1449–54. - DOI

MeSH terms

LinkOut - more resources